Entrada Therapeutics, Inc.
- Open
- 6.86
- Day high
- 6.98
- Day low
- 6.64
- Prev close
- 6.87
- Volume
- 377K
- Mkt cap
- $267M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.0
- P/S
- 46.6
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$599K over the last 3 months (1 open-market buy, 2 sales)
- 🏛Institutions mixed (13F)
Entrada Therapeutics, Inc. (TRDA) is a Healthcare company listed on NASDAQ. The stock is up 10% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 2 sales (SEC Form 4).
Entrada Therapeutics, Inc. (TRDA) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TRDA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-1.06 | $-0.95 | +10.4% | $875000 | -70.0% |
| Nov 6, 2025 | $-1.04 | $-1.06 | -1.9% | $2M | -81.0% |
| Aug 6, 2025 | $-0.86 | $-1.04 | -20.9% | $2M | -75.1% |
| May 8, 2025 | $-0.78 | $-0.42 | +46.2% | $21M | +110.4% |
| Feb 27, 2025 | $-0.66 | $0.03 | +104.5% | $37M | +185.0% |
| Mar 13, 2024 | $-0.07 | $-0.29 | -314.3% | $42M | +76.6% |
| Mar 6, 2023 | $-0.84 | $-0.79 | +6.0% | — | — |
| Aug 11, 2022 | $-0.72 | $-0.74 | -2.8% | — | — |
| May 12, 2022 | $-0.65 | $-0.69 | -6.2% | — | — |
| Mar 15, 2022 | $-1.28 | $-0.89 | +30.5% | — | — |
| Dec 9, 2021 | $-0.87 | $-9.78 | -1024.1% | — | — |
| Mar 31, 2021 | — | $-0.41 | — | — | — |
TRDA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Chapman Ginadirector | Grant | 19,000 | $5.97 |
| Jun 12, 2026 | Thistle Marydirector | Grant | 19,000 | $5.97 |
| Jun 12, 2026 | PARMAR KUSHdirector, 10 percent owner: | Grant | 19,000 | $5.97 |
| Jun 12, 2026 | Radhakrishnan Mahadirector | Grant | 19,000 | $5.97 |
| Jun 12, 2026 | KIM PETER Sdirector | Grant | 19,000 | $5.97 |
| Jun 12, 2026 | Zeiher Bernhardt Gdirector | Grant | 19,000 | $5.97 |
| May 21, 2026 | Zeiher Bernhardt Gdirector | Buy | 5,000 | $5.86 |
| May 4, 2026 | Sethuraman Natarajanofficer: President, Research & Develop. | Sell | 25,907 | $15.39 |
| May 4, 2026 | Dowden Nathan Jofficer: President & COO | Sell | 15,000 | $15.33 |
| May 4, 2026 | Dowden Nathan Jofficer: President & COO | Option | 15,000 | $1.74 |
| Apr 2, 2026 | WENTWORTH KORY JAMESofficer: Chief Financial Officer | Sell | 2,500 | $12.95 |
| Mar 11, 2026 | Dowden Nathan Jofficer: President & COO | Sell | 11,894 | $13.05 |
| Mar 11, 2026 | WENTWORTH KORY JAMESofficer: Chief Financial Officer | Sell | 11,388 | $13.02 |
| Mar 11, 2026 | WENTWORTH KORY JAMESofficer: Chief Financial Officer | Sell | 5,089 | $13.00 |
| Mar 11, 2026 | Dowden Nathan Jofficer: President & COO | Sell | 3,116 | $13.02 |
Source: TRDA SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full TRDA insider & 13F page →Entrada Therapeutics, Inc. company profile
Overview
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company founded in 2016 and headquartered in Boston, Massachusetts. Originally incorporated as CycloPorters, Inc., the company changed its name to Entrada Therapeutics in October 2017 and went public in October 2021. Entrada focuses on developing innovative therapeutics for neuromuscular diseases using its proprietary endosomal escape vehicle (EEV) platform technology. The company represents an emerging player in the specialized field of intracellular drug delivery, targeting conditions where traditional therapies have struggled to achieve adequate cellular penetration.
Business
Entrada Therapeutics operates in the biotechnology sector, specifically focusing on developing treatments for neuromuscular diseases through its proprietary endosomal escape vehicle (EEV) platform. To understand what this means, it's important to know that many potential drugs face a fundamental challenge: they cannot effectively penetrate into cells where they need to work. When drugs are taken up by cells, they often become trapped in cellular compartments called endosomes, preventing them from reaching their intended targets. Entrada's EEV technology solves this problem by helping therapeutic molecules escape from these cellular compartments and reach their destinations inside cells. The platform can deliver three main types of therapeutic molecules: oligonucleotides (short DNA or RNA sequences that can modify gene expression), antibodies (proteins that can bind to specific targets), and enzymes (proteins that catalyze biochemical reactions). The company's lead product candidate is ENTR-601-44, currently in preclinical development for treating Duchenne muscular dystrophy and myotonic dystrophy type 1. Duchenne muscular dystrophy is a severe genetic disorder causing progressive muscle degeneration, while myotonic dystrophy type 1 is a multisystem disorder affecting muscles, heart, and other organs. Entrada is also developing EEV-PMO-CAG specifically for myotonic dystrophy type 1. These conditions represent significant unmet medical needs where current treatments are limited or nonexistent.
Revenue model
Entrada Therapeutics generates revenue primarily through collaboration agreements and licensing deals with pharmaceutical partners, rather than through direct product sales, as its therapeutic candidates are still in development phases. The company's business model is typical of early-stage biotechnology firms, where revenue comes from upfront payments, milestone payments, and potential future royalties from partnership agreements. Based on the financial data, Entrada has shown significant revenue variability, with 2024 full-year revenue reaching $210.8 million compared to $129.0 million in 2023 and zero revenue in 2022. This lumpy revenue pattern is characteristic of biotech companies dependent on partnership milestones and collaboration payments. The company's paying customers are primarily large pharmaceutical companies seeking to leverage Entrada's EEV platform technology for their own drug development programs. Several factors could impact Entrada's margins and revenue generation. Positive factors include successful clinical trial results that could trigger milestone payments, expansion of the partnership portfolio, and validation of the EEV platform across multiple therapeutic areas. The growing interest in precision medicine and targeted therapies also creates favorable market conditions. Negative factors include the inherent risks of drug development where clinical failures could halt milestone payments, competitive pressure from other drug delivery technologies, regulatory challenges that could delay programs, and the company's dependence on a limited number of partnerships for revenue generation.
Competitive moat
Entrada Therapeutics' competitive moat centers around its proprietary endosomal escape vehicle (EEV) platform technology, which represents a potentially differentiated approach to intracellular drug delivery. The company's moat strength appears moderate, built primarily on intellectual property protection around its EEV technology and the specialized expertise required to develop and optimize these delivery systems. The platform's versatility in delivering different types of therapeutic molecules (oligonucleotides, antibodies, and enzymes) provides some breadth of application, potentially making it valuable across multiple therapeutic areas. However, the moat faces several challenges. The drug delivery space is highly competitive, with numerous companies developing alternative approaches to intracellular delivery, including lipid nanoparticles, viral vectors, and other proprietary delivery systems. Large pharmaceutical companies also have substantial internal capabilities and resources to develop competing technologies. The ultimate strength of Entrada's moat will depend on clinical validation of its EEV platform. If the technology demonstrates superior efficacy and safety compared to existing delivery methods, it could establish a stronger competitive position. However, until clinical proof-of-concept is achieved, the moat remains largely theoretical. The company's early-stage development status means it faces typical biotech risks including clinical failure, regulatory hurdles, and the possibility that competing technologies may prove superior. Additionally, the specialized nature of neuromuscular diseases, while representing unmet need, also limits the addressable market size compared to more prevalent conditions.
Risks & safety
Entrada Therapeutics presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong balance sheet metrics but inherent development risks. • Cash position and solvency: The company maintains a solid cash position with $101.2 million in cash and short-term investments as of Q4 2024, though this declined from $185.3 million in Q2 2024. Current ratio of 11.1x indicates strong short-term liquidity. • Debt levels: Low debt burden with debt-to-equity ratio of 0.14, indicating minimal financial leverage and reduced solvency risk. • Cash burn: Negative free cash flow of $44.7 million for 2024 suggests ongoing cash consumption for R&D activities, though this is typical for development-stage biotech companies. • Valuation metrics: Trading at price-to-book ratio of 1.50 and price-to-earnings ratio of 9.8 based on 2024 results, though earnings were boosted by partnership revenue that may not be recurring. • Other considerations: Revenue volatility creates uncertainty about sustainable cash generation, and the company's dependence on partnership agreements for funding introduces execution risk. The early-stage nature of lead programs means clinical and regulatory risks remain substantial.
Recent development
Based on the available financial data, Entrada Therapeutics has made significant progress in establishing its business model around partnership collaborations over the past few years. The most notable development has been the company's transition from a pure R&D entity with zero revenue in 2022 to generating substantial partnership revenue, reaching $210.8 million in 2024. This revenue growth reflects the company's success in securing collaboration agreements that validate its EEV platform technology. The significant revenue spike in Q2 2024 ($94.7 million) followed by more modest quarterly revenues suggests the company received substantial upfront or milestone payments from partnerships during that period. This pattern indicates Entrada has been successful in attracting pharmaceutical partners interested in leveraging its drug delivery technology. The company has maintained focus on its core neuromuscular disease programs, with continued development of ENTR-601-44 for Duchenne muscular dystrophy and myotonic dystrophy type 1, as well as advancement of EEV-PMO-CAG for myotonic dystrophy type 1. The consistent investment in R&D, evidenced by ongoing negative operating cash flows despite partnership revenues, demonstrates the company's commitment to advancing its pipeline while building its platform technology for broader applications.
TRDA company profile · for informational purposes only — not investment advice.
Track TRDA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free